Verrica Pharmaceuticals shares rise 11.02% intraday after upgrade to Strong Buy on improved earnings outlook.

Verrica Pharmaceuticals (VRCA) surged 11.02% intraday following its upgrade to a Zacks Rank #1 (Strong Buy), signaling heightened optimism about its earnings potential. The upgrade, which reflects analysts’ improved outlook on the biopharmaceutical company’s financial prospects, directly aligned with the stock’s sharp intraday rally. No other news events were provided that could explain the movement, and the sole relevant development—its Zacks Rank adjustment—was explicitly bullish and consistent with the upward price trajectory.